Ghana vs Madagascar: Average cost of multi drug-resistant tuberculosis treatment
Ghana
500 constant 2022 US$
in 2024
Madagascar
532 constant 2022 US$
in 2024
Ghana rank
78th
Madagascar rank
77th
Average cost of multi drug-resistant tuberculosis treatment over time
- Ghana
- Madagascar
How they compare
Madagascar currently reports 532 constant 2022 US$ against 500 constant 2022 US$ in Ghana, a difference of 32 constant 2022 US$.
That makes Madagascar's figure about 1.1 times Ghana's.
The two have swapped places 2 times across 8 shared years of data; in 2017 it was Madagascar ahead.
Ghana ranks 78th and Madagascar ranks 77th of 92 countries.
Ghana has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Ghana | Madagascar | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,860 constant 2022 US$ | 1,509 constant 2022 US$ | 351 constant 2022 US$ | Ghana |
| 2020s | 1,116 constant 2022 US$ | 622.2 constant 2022 US$ | 493.6 constant 2022 US$ | Ghana |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Ghana or Madagascar?
- Madagascar, at 532 constant 2022 US$ against 500 constant 2022 US$ in Ghana as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Ghana and Madagascar?
- 32 constant 2022 US$, with Madagascar ahead.
- How many years of comparable data are there for Ghana and Madagascar?
- 8 years are reported by both, from 2017 to 2024.
- How do Ghana and Madagascar rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Ghana ranks 78th and Madagascar ranks 77th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.